MIRIS: Green Growth in the Midst of a Pandemic
23.9.2020 17:19:00 EEST | Business Wire | Press release
In March 2020, also Norway ran out of infection control equipment. In this critical phase, MIRIS, a top tier technology green real estate company, initiated a collaboration with China Development Integration Limited (CDIL), a major EPC integration corporation in the Silk Road initiative.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005669/en/
From left to right: Henrik Berg Klemmetsen, Magdalena Urbanik, Danny Wong, Andy Lai , Davis Chiu Xinwen Chang and Jan Gunnar Mathisen. Frame: Edmund Amir. (Photo: Business Wire)
The two companies have a relationship with regards to building a large-scale smart city in Europe, and MIRIS realized the possibility of a cooperation with CDIL and its resources to ensure supply of high quality infection control equipment.
Together they fulfilled significant contracts regarding infection control equipment for several countries, including Norway.
In a market described as the "Wild West", this collaboration tells a different story. They controlled the entire value chain, and ensured deliveries without problems. Even a pandemic can create trust and cooperation that triggers new growth and development.
First of all, CDIL and MIRIS will further develop the infection control equipment collaboration under the ”Protect” brand – with the slogan; “Safe to buy – Safe to use”.
Secondly, they will ensure 12 months of high-volume deliveries of necessary equipment at high quality and competitive prices to Northern Europe.
Thirdly, they will ensure that as many people as possible have access to infection control equipment, and will distribute 10 million infection control masks free of charge to voluntary organizations. Many of these have been hit hard by the pandemic, and will be able to resell the masks to earn income in a demanding time, or distribute them free of charge to people for whom infection control equipment becomes too expensive.
Last but not the least, the companies will join forces to look at the possibilities of developing disposable infection control equipment that is degradable, so as to reduce the environmental impact.
The long-term goal of the two companies’ collaboration goes beyond infection control equipment: Sustainable healthy cities.
Building for a Sustainable Future
To create or reinvent a green city, the first step is to define the energy demand of this city. Energy saving and building optimization, can reduce the demand dramatically. The city will be digitized, and over 95 percent of the energy from the data centers will be reused as heat. With modern solar cell technology and energy saving, the city will become energy-positive: It will produce more energy than it consumes.
The necessary technology already exists. But it needs people who are able to put it together at competitive prices, and who have enough capital and ability to implement it. “CDIL and MIRIS are leading the way at a turning point. This cooperation mutually beneficial for both parties is the best way to solve the challenges of the future. MIRIS has the technology ready, and projects testing is underway,” says Mr. Lai, Chairman of CDIL.
CDIL will contribute capital, market access and other EPC resources to create green growth along the entire new Silk Road. A collaboration of two companies each with their respective distinctive resources will create huge gains for the community, and hopefully the whole world.
Jan Gunnar Mathisen, CEO, founder and majority owner of MIRIS, emphasizes the opportunities created for green finance.
“This signals the change of direction that is now underway. If in the future all countries stress green investments, everything will change”, says Mathisen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005669/en/
Contact information
Further inquiries:
Asbjorn Ness Miris
+ 47 47 26 10 20
asbjorn.ness@miris.no
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 04:00:00 EEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202628.5.2026 00:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, senior author of the NEJM manuscript and first author of the ASCO abstract, said: “Results from the HERIZON-GEA-01 published in The New England Journal of Medicine and presented in an oral presentation at ASCO provide ne
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 18:22:00 EEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 17:00:00 EEST | Press release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 16:00:00 EEST | Press release
ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527813115/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov Growth When ClickHouse closed its $400 million Series D in January 2026, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
